- Molecular NameTrimipramine
- Synonymbeta-Methylimipramine; Trimeprimina [Italian]; Trimeprimine; Trimipramina [INN-Spanish]; Trimipraminum [INN-Latin]
- Weight294.442
- Drugbank_IDDB00726
- ACS_NO739-71-9
- Show 2D model
- LogP (experiment)4.82
- LogP (predicted, AB/LogP v2.0)4.9
- pkaN/A
- LogD (pH=7, predicted)2.74
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.62
- LogSw (predicted, AB/LogsW2.0)0.02
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors0
- No.of HBond Acceptors2
- No.of Rotatable Bonds4
- TPSA6.48
- StatusFDA approved
- AdministrationOral, IM, IV
- PharmacologyA psychoactive drug of the tricyclic antidepressant (TCA) chemical class with antidepressant, anxiolytic, antipsychotic, sedative, and analgesic effects.
- Absorption_value80.0
- Absorption (description)Rapid absorption
- Caco_2N/A
- Bioavailability40.0
- Protein binding94.0
- Volume of distribution (VD)20 to 50 L/kg (mean 30)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life24 h
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting
- LD50 (rat)N/A
- LD50 (mouse)N/A